ClinicalTrials.gg
Active, not recruitingNCT01804686CAN3001Updated Nov 3, 2026

A Long-term Extension Study of PCI-32765 (Ibrutinib)

A Phase 3 interventional study of Ibrutinib in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Mantle Cell Lymphoma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 156 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Now Active, not recruitingNo longer in Italy+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
539
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
4th of 83
539 · median 44
Started
2013
with 6 others
Phase 3
14 of 83
none open now
Primary completion
2026-12
later than 16 of 27 live
Registered
15th of 83
by date
Lead sponsor
8 of 83
Janssen Research & Development, LLC

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 7 that started in 2013, is one of 14 in phase 3, reaches primary completion later than 16 of the 27 other live ones, and was the 15th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Read the detailed description

This is an open-label (identity of assigned study drug will be known) study designed to collect long-term safety and efficacy data and provide ibrutinib access to participants in completed ibrutinib studies. PCI-32765 (Ibrutinib) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of bruton's tyrosine kinase. "PCI-32765" and "ibrutinib" refer to the same molecule; hereafter, "ibrutinib" will be used. Participants will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study until the investigator determines that the participant is no longer benefitting from treatment (ie, disease progression or unacceptable toxicity has occurred), the participant withdraws consent, alternative access to ibrutinib is available and feasible (example, participant assistance program or commercial source of ibrutinib), or for other reasons as defined in the protocol, or until the end of the study, whichever occurs earlier. Safety will be monitored throughout the study and summarized. Efficacy may be analyzed in combination with the data collected in the parent protocol. There is no formal hypothesis testing planned for this long-term extension study. Participants for whom alternative access to ibrutinib is not available and feasible can receive treatment with single-agent ibrutinib until end of study, which is defined as the time when all participants still receiving study treatment have transitioned to commercial or alternative access to ibrutinib, have stopped receiving ibrutinib treatment, or upon a decision by the sponsor to terminate the study, whichever occurs earlier.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Chronic Graft Versus Host Disease

Keywords

  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
  • Mantle cell lymphoma
  • Follicular lymphoma
  • Diffuse large B-cell lymphoma
  • PCI-32765
  • Ibrutinib
  • Bruton's tyrosine kinase inhibitor
  • IMBRUVICA
  • JNJ-54179060
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be currently participating in an ibrutinib clinical study considered complete and have received at least 6 months of treatment with ibrutinib. At study entry, participants must be actively receiving treatment with single-agent ibrutinib; or participants must have participated in an ibrutinib randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior ibrutinib treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessments; or participants must be currently participating in study PCI-32765LYM1002. At study entry, participants must be actively receiving combination treatment with ibrutinib and nivolumab or single-agent ibrutinib
  • Investigator's assessment that the benefit of continued ibrutinib therapy as a single agent or in combination with nivolumab will outweigh the risks
  • Agrees to protocol-defined use of effective
  • Negative blood or urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists
  • Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors, unless previously approved by sponsor
  • Any condition or situation which, in the opinion of the investigator, may put the participant at significant risk, may confound the study results, or may interfere significantly with volunteer's participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
539 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Drug: Ibrutinib

Interventions

  • Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.

    Also known as: PCI-32765

06

What researchers measure

Primary outcomes

  1. Number of participants affected by an adverse event

    Time frame: Up to 30 days after the last dose of study drug, or until the start of a subsequent systemic anti-cancer therapy, if earlier

Secondary outcomes

  1. Number of participants with change in disease status

    Time frame: Up to the end-of-treatment visit (up to 30 days after the last dose of study medication), or until the start of a subsequent anti-caner therapy, if earlier

07

Study locations

156 sites
  • Duarte, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Stanford, California, United States
  • Norwalk, Connecticut, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Goshen, Indiana, United States
  • Westwood, Kansas, United States
  • Louisville, Kentucky, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Battle Creek, Michigan, United States
  • Detroit, Michigan, United States
  • St Louis, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Hackensack, New Jersey, United States
  • New York, New York, United States
  • Goldsboro, North Carolina, United States
  • Columbus, Ohio, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Sioux Falls, South Dakota, United States
  • Houston, Texas, United States
  • Charlottesville, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Madison, Wisconsin, United States
  • Ciudad Autonoma Buenos Aires, Argentina
  • Ciudad de Buenos Aires, Argentina
  • Adelaide, Australia
  • Coburg, Australia
  • Concord, Australia
  • Heidelberg, Australia
  • Melbourne, Australia
  • Perth, Australia
  • Prahran, Australia
  • Wahroonga, Australia
  • Antwerp, Belgium
  • Bruges, Belgium
  • Brussels, Belgium
  • Ghent, Belgium
  • Leuven, Belgium
  • Yvoir, Belgium
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • São Paulo, Brazil
  • Montreal, Quebec, Canada
  • Beijing, China
  • Chengdu, China
  • Fuzhou, China
  • Guangzhou, China
  • Hangzhou, China
  • Shanghai, China
  • Shanxi, China
  • Suzhou, China
  • Tianjin, China
  • Wuhan, China
  • Bogotá, Colombia
  • Floridablanca, Colombia
  • Brno, Czechia
  • Prague, Czechia
  • Créteil, France
  • Mulhouse, France
  • Paris, France
  • Pessac, France
  • Pierre-Bénite, France
  • Tours, France
  • Berlin, Germany
  • Dresden, Germany
  • Essen, Germany
  • Giessen, Germany
  • Heidelberg, Germany
  • Homburg/Saar, Germany
  • Magdeburg, Germany
  • Marburg, Germany
  • Ulm, Germany
  • Athens, Greece
  • Thessalonikis, Greece
  • Budapest, Hungary
  • Szeged, Hungary
  • Dublin, Ireland
  • Afula, Israel
  • Hadera, Israel
  • Haifa, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Tel Aviv, Israel
  • Bunkyō City, Japan
  • Hiroshima, Japan
  • Oaxaca City, Mexico
  • Amsterdam, Netherlands
  • Brzozów, Poland
  • Chorzów, Poland
  • Gdansk, Poland
  • Klinika Nowotworow Ukladu Chlonnego, Poland
  • Krakow, Poland
  • Opole, Poland

Showing the first 100 of 156 sites across 29 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for Dec 2026, 159 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 159 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2013
First posted
Mar 5, 2013
StartActual
Sep 9, 2013
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 1, 2026
Sites
156 sites added, 175 sites removed; no longer in Italy
Show 156 added (30 United States, 15 Russia, 14 United Kingdom, 10 China, 9 Germany, 8 Australia, 8 Poland, 7 Ukraine, 6 Belgium, 6 France, 6 Israel, 5 Spain, 4 Turkey (Türkiye), 3 Brazil, 3 Sweden, 2 Argentina, 2 Colombia, 2 Czechia, 2 Greece, 2 Hungary, 2 Japan, 2 Portugal, 2 South Korea, 1 Canada, 1 Ireland, 1 Mexico, 1 Netherlands, 1 Puerto Rico, 1 Taiwan)
  • Duarte · Duarte, United States
  • La Jolla · La Jolla, United States
  • Los Angeles · Los Angeles, United States
  • Orange · Orange, United States
  • Stanford · Stanford, United States
  • Norwalk · Norwalk, United States
  • Marietta · Marietta, United States
  • Chicago · Chicago, United States
  • Goshen · Goshen, United States
  • Westwood · Westwood, United States
  • Louisville · Louisville, United States
  • Boston · Boston, United States
  • Ann Arbor · Ann Arbor, United States
  • Battle Creek · Battle Creek, United States
  • Detroit · Detroit, United States
  • St Louis · St Louis, United States
  • Lebanon · Lebanon, United States
  • Hackensack · Hackensack, United States
  • New York · New York, United States
  • Goldsboro · Goldsboro, United States
  • Columbus · Columbus, United States
  • Eugene · Eugene, United States
  • Portland · Portland, United States
  • Philadelphia · Philadelphia, United States
  • Sioux Falls · Sioux Falls, United States
  • Houston · Houston, United States
  • Charlottesville · Charlottesville, United States
  • Seattle · Seattle, United States
  • Morgantown · Morgantown, United States
  • Madison · Madison, United States
  • …and 126 more on the registry record
Show 175 removed
  • City of Hope Cancer Center · Duarte, United States
  • University of California San Diego Medical Center · La Jolla, United States
  • University of California Los Angeles · Los Angeles, United States
  • St. Joseph Hospital Center for Cancer Prevention and Treatment · Orange, United States
  • Stanford University Medical Center · Stanford, United States
  • Stanford University · Stanford, United States
  • Norwalk Medical Group · Norwalk, United States
  • Northwest Georgia Oncology Centers PC · Marietta, United States
  • Northwestern University Hospital · Chicago, United States
  • Indiana University · Goshen, United States
  • Kansas University Medical Center · Westwood, United States
  • Louisville Oncology Suburban - Norton Cancer Institute · Louisville, United States
  • Dana Farber Cancer Center · Boston, United States
  • University of Michigan Comprehensive Cancer Center · Ann Arbor, United States
  • Battle Creek Health Systm · Battle Creek, United States
  • Karmanos Cancer Institute - Wayne State University · Detroit, United States
  • Washington University · St Louis, United States
  • Dartmouth Hitchcock Medical Center · Lebanon, United States
  • Hackensack University Medical Center · Hackensack, United States
  • Weill Medical College of Cornell University · New York, United States
  • Memorial Sloan-Kettering Cancer Center · New York, United States
  • Southeastern Medical Oncology Center · Goldsboro, United States
  • The Ohio State University- James Cancer Hospital · Columbus, United States
  • Willamette Valley Cancer Center · Eugene, United States
  • Kaiser Permanente · Portland, United States
  • University of Pennsylvania Medical Center · Philadelphia, United States
  • Avera Medical Group · Sioux Falls, United States
  • MD Anderson Cancer Center - University of Texas · Houston, United States
  • University of Virginia · Charlottesville, United States
  • University of Washington · Seattle, United States
  • …and 145 more on the registry record
Nov 3, 2026
Enrollment
700 (estimated)→539 (actual)
Oct 1, 2026
Show all 2 updates
  1. Nov 3, 2026
    156 sites added, 175 sites removed; no longer in Italy
    Show 156 added (30 United States, 15 Russia, 14 United Kingdom, 10 China, 9 Germany, 8 Australia, 8 Poland, 7 Ukraine, 6 Belgium, 6 France, 6 Israel, 5 Spain, 4 Turkey (Türkiye), 3 Brazil, 3 Sweden, 2 Argentina, 2 Colombia, 2 Czechia, 2 Greece, 2 Hungary, 2 Japan, 2 Portugal, 2 South Korea, 1 Canada, 1 Ireland, 1 Mexico, 1 Netherlands, 1 Puerto Rico, 1 Taiwan)
    • Duarte · Duarte, United States
    • La Jolla · La Jolla, United States
    • Los Angeles · Los Angeles, United States
    • Orange · Orange, United States
    • Stanford · Stanford, United States
    • Norwalk · Norwalk, United States
    • Marietta · Marietta, United States
    • Chicago · Chicago, United States
    • Goshen · Goshen, United States
    • Westwood · Westwood, United States
    • Louisville · Louisville, United States
    • Boston · Boston, United States
    • Ann Arbor · Ann Arbor, United States
    • Battle Creek · Battle Creek, United States
    • Detroit · Detroit, United States
    • St Louis · St Louis, United States
    • Lebanon · Lebanon, United States
    • Hackensack · Hackensack, United States
    • New York · New York, United States
    • Goldsboro · Goldsboro, United States
    • Columbus · Columbus, United States
    • Eugene · Eugene, United States
    • Portland · Portland, United States
    • Philadelphia · Philadelphia, United States
    • Sioux Falls · Sioux Falls, United States
    • Houston · Houston, United States
    • Charlottesville · Charlottesville, United States
    • Seattle · Seattle, United States
    • Morgantown · Morgantown, United States
    • Madison · Madison, United States
    • …and 126 more on the registry record
    Show 175 removed
    • City of Hope Cancer Center · Duarte, United States
    • University of California San Diego Medical Center · La Jolla, United States
    • University of California Los Angeles · Los Angeles, United States
    • St. Joseph Hospital Center for Cancer Prevention and Treatment · Orange, United States
    • Stanford University Medical Center · Stanford, United States
    • Stanford University · Stanford, United States
    • Norwalk Medical Group · Norwalk, United States
    • Northwest Georgia Oncology Centers PC · Marietta, United States
    • Northwestern University Hospital · Chicago, United States
    • Indiana University · Goshen, United States
    • Kansas University Medical Center · Westwood, United States
    • Louisville Oncology Suburban - Norton Cancer Institute · Louisville, United States
    • Dana Farber Cancer Center · Boston, United States
    • University of Michigan Comprehensive Cancer Center · Ann Arbor, United States
    • Battle Creek Health Systm · Battle Creek, United States
    • Karmanos Cancer Institute - Wayne State University · Detroit, United States
    • Washington University · St Louis, United States
    • Dartmouth Hitchcock Medical Center · Lebanon, United States
    • Hackensack University Medical Center · Hackensack, United States
    • Weill Medical College of Cornell University · New York, United States
    • Memorial Sloan-Kettering Cancer Center · New York, United States
    • Southeastern Medical Oncology Center · Goldsboro, United States
    • The Ohio State University- James Cancer Hospital · Columbus, United States
    • Willamette Valley Cancer Center · Eugene, United States
    • Kaiser Permanente · Portland, United States
    • University of Pennsylvania Medical Center · Philadelphia, United States
    • Avera Medical Group · Sioux Falls, United States
    • MD Anderson Cancer Center - University of Texas · Houston, United States
    • University of Virginia · Charlottesville, United States
    • University of Washington · Seattle, United States
    • …and 145 more on the registry record
    + 1 other change: verification date
  2. Oct 1, 2026
    Recruiting→Active, not recruiting
    Enrollment 700 (estimated)→539 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01804686
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 5, 2013
Start date
Sep 9, 2013
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion